tiprankstipranks
Advertisement
Advertisement

GB:0MH6 Stock Latest News

Ipsen Reports Modest Share Buybacks in Late August 2026
Company AnnouncementsIpsen Reports Modest Share Buybacks in Late August 2026
2d ago
Ipsen Reports No Share Buybacks in Week of 17–21 August 2026
PremiumCompany Announcements
Ipsen Reports No Share Buybacks in Week of 17–21 August 2026
9d ago
Ipsen boosts hematology pipeline with Kartos Therapeutics acquisition
PremiumCompany Announcements
Ipsen boosts hematology pipeline with Kartos Therapeutics acquisition
13d ago
Ipsen updates investors on July 2026 share capital and voting rights
PremiumCompany Announcements
Ipsen updates investors on July 2026 share capital and voting rights
13d ago
Ipsen Executes €156-Averaged Share Buyback Across European Markets
PremiumCompany Announcements
Ipsen Executes €156-Averaged Share Buyback Across European Markets
16d ago
Ipsen Buys Back 17,818 Shares in Early August Under MAR Rules
PremiumCompany AnnouncementsIpsen Buys Back 17,818 Shares in Early August Under MAR Rules
23d ago
Ipsen Reports Share Buybacks on Euronext Paris in Late July 2026
Premium
Company Announcements
Ipsen Reports Share Buybacks on Euronext Paris in Late July 2026
1M ago
Ipsen: Strong Execution and Raised 2026 Guidance Support Buy Rating; €235 Price Target Reiterated
Premium
Ratings
Ipsen: Strong Execution and Raised 2026 Guidance Support Buy Rating; €235 Price Target Reiterated
1M ago
Ipsen lifts 2026 guidance on strong H1 results and pipeline-boosting deals
PremiumCompany Announcements
Ipsen lifts 2026 guidance on strong H1 results and pipeline-boosting deals
1M ago
Ipsen Strengthens Board with Appointment of Governance Expert Catherine Bradley
PremiumCompany Announcements
Ipsen Strengthens Board with Appointment of Governance Expert Catherine Bradley
1M ago
Ipsen Reports Share Buybacks Totaling 13,930 Shares Over Late July
PremiumCompany Announcements
Ipsen Reports Share Buybacks Totaling 13,930 Shares Over Late July
1M ago
Ipsen’s Bylvay misses Phase III goal in biliary atresia, limiting expansion bid
PremiumCompany Announcements
Ipsen’s Bylvay misses Phase III goal in biliary atresia, limiting expansion bid
1M ago
Ipsen Corrects June 2026 Voting Rights and Share Capital Disclosure
PremiumCompany AnnouncementsIpsen Corrects June 2026 Voting Rights and Share Capital Disclosure
1M ago
Ipsen buys Memo Therapeutics to add first-in-class BK virus antibody
Premium
Company Announcements
Ipsen buys Memo Therapeutics to add first-in-class BK virus antibody
1M ago
Ipsen: Buy Rating Reiterated on BEOND Phase 3 Migraine Data; €235 Price Target Maintained
Premium
Ratings
Ipsen: Buy Rating Reiterated on BEOND Phase 3 Migraine Data; €235 Price Target Maintained
2M ago
PremiumRatings
Ipsen Price Target Raised to €235 as Navtemadlin ‘Rux-Rescue’ Strategy and Kartos Acquisition Support Buy Rating
2M ago
PremiumRatings
Ram Selvaraju Reiterates Buy on Ipsen, Sets €215 12‑Month Price Target on Diversified Oncology and Rare Liver Disease Growth Drivers
3M ago
PremiumRatings
Benjamin Jackson Reiterates Hold on Ipsen as Corabotase Data Show Limited Differentiation from Next‑Gen Neurotoxins
4M ago
PremiumCompany Announcements
Ipsen’s corabotase shows prolonged effect and high satisfaction in phase II glabellar lines trial
4M ago
Ipsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis
PremiumCompany AnnouncementsIpsen’s Luminaria Study: Fresh Digital Symptom Data in Primary Biliary Cholangitis
5M ago
0MH6
Ipsen’s IPN10200 Phase 3 Aesthetics Trial: What Investors Should Watch
Premium
Company Announcements
Ipsen’s IPN10200 Phase 3 Aesthetics Trial: What Investors Should Watch
6M ago
0MH6
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
Premium
Company Announcements
Ipsen Advances Elafibranor Into Phase III For Rare Liver Disease, Signaling Long-Term Upside Potential
6M ago
0MH6

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >